C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021
10 avr. 2021 15h05 HE
|
C4 Therapeutics, Inc.
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – –...
C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results
11 mars 2021 16h01 HE
|
C4 Therapeutics, Inc.
– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of...
C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting
10 mars 2021 16h41 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
C4 Therapeutics to Participate in Upcoming March Investor Conferences
24 févr. 2021 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
C4 Therapeutics to Participate in BMO BioPharma Spotlight Series
11 févr. 2021 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies
19 janv. 2021 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
07 janv. 2021 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively...
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
06 janv. 2021 07h00 HE
|
C4 Therapeutics, Inc.
– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial...
C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
17 déc. 2020 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys...
C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx
25 nov. 2020 07h00 HE
|
C4 Therapeutics, Inc.
WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys...